ATE440864T1 - Verwendung von il-23-antagonisten; verwandte reagenzien - Google Patents

Verwendung von il-23-antagonisten; verwandte reagenzien

Info

Publication number
ATE440864T1
ATE440864T1 AT04718824T AT04718824T ATE440864T1 AT E440864 T1 ATE440864 T1 AT E440864T1 AT 04718824 T AT04718824 T AT 04718824T AT 04718824 T AT04718824 T AT 04718824T AT E440864 T1 ATE440864 T1 AT E440864T1
Authority
AT
Austria
Prior art keywords
antagonists
related reagents
methods
reagents
tumors
Prior art date
Application number
AT04718824T
Other languages
English (en)
Inventor
Martin Oft
Terrill Mcclanahan
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE440864T1 publication Critical patent/ATE440864T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
AT04718824T 2003-03-10 2004-03-09 Verwendung von il-23-antagonisten; verwandte reagenzien ATE440864T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45367203P 2003-03-10 2003-03-10
PCT/US2004/007198 WO2004081190A2 (en) 2003-03-10 2004-03-09 Uses of il-23 agonists and antagonists; related reagents

Publications (1)

Publication Number Publication Date
ATE440864T1 true ATE440864T1 (de) 2009-09-15

Family

ID=32990805

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04718824T ATE440864T1 (de) 2003-03-10 2004-03-09 Verwendung von il-23-antagonisten; verwandte reagenzien

Country Status (23)

Country Link
US (4) US7282204B2 (de)
EP (2) EP2108658B1 (de)
JP (4) JP4605798B2 (de)
CN (1) CN1759123B (de)
AT (1) ATE440864T1 (de)
AU (2) AU2004219625B9 (de)
BR (1) BRPI0408247A (de)
CA (1) CA2518262C (de)
CL (1) CL2004000467A1 (de)
CY (1) CY1109468T1 (de)
DE (1) DE602004022781D1 (de)
DK (1) DK1601694T3 (de)
ES (1) ES2330220T3 (de)
HK (1) HK1076477A1 (de)
MX (1) MXPA05009717A (de)
NO (1) NO20054630D0 (de)
NZ (2) NZ541898A (de)
PL (1) PL1601694T3 (de)
PT (1) PT1601694E (de)
SI (1) SI1601694T1 (de)
TW (2) TWI357336B (de)
WO (1) WO2004081190A2 (de)
ZA (1) ZA200506879B (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2501786C (en) 2002-10-30 2015-02-17 Genentech, Inc. Inhibition of il-17 production
TWI357336B (en) * 2003-03-10 2012-02-01 Schering Corp Uses of il-23 agonists and antagonists; related re
AU2004239288B2 (en) * 2003-05-09 2010-01-28 Centocor, Inc. IL-23p40 specific immunoglobulin derived proteins, compositions, methods and uses
CN1942201B (zh) * 2004-02-17 2012-06-20 先灵公司 调节il-23活性的方法；相关试剂
US20060193821A1 (en) * 2004-03-05 2006-08-31 Diener John L Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
AU2005220910A1 (en) * 2004-03-05 2005-09-22 Archemix Corp. Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
AR051444A1 (es) * 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
TWI363091B (en) 2004-12-20 2012-05-01 Schering Corp Uses of mammalian cytokine; related reagents
US20090142855A1 (en) * 2005-06-30 2009-06-04 Wei Tang Polynucleotides and Polypeptides of the IL-12 Family of Cytokines
AU2012258409B2 (en) * 2005-06-30 2016-01-07 Centocor, Inc. Anti-IL-23 antibodies, compositions, methods and uses
HUE042561T2 (hu) 2005-06-30 2019-07-29 Janssen Biotech Inc Anti-IL-23-ellenanyagok, készítmények, eljárások és alkalmazások
CA2619052A1 (en) * 2005-08-25 2007-03-01 Eli Lily And Company Anti-il-23 antibiodies
EP3190125A1 (de) 2005-08-31 2017-07-12 Merck Sharp & Dohme Corp. Mittels engineering hergestellte anti-il-23r-antikörper
ES2333260T3 (es) 2005-09-01 2010-02-18 Schering Corporation Uso de antagonistas de il-23 e il-17 para tratar la enfermedad inflamatoria ocular autoinmunologica.
DK3219328T3 (da) 2005-12-29 2020-07-13 Janssen Biotech Inc Humane anti-il-23-antistoffer, sammensætninger, fremgangsmåder og anvendelser
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
JP2009540018A (ja) 2006-06-13 2009-11-19 ザイモジェネティクス， インコーポレイテッド Ｉｌ−１７およびｉｌ−２３アンタゴニストならびにその使用方法
EP1882699A1 (de) * 2006-07-27 2008-01-30 Heinfried Radeke Regulation von Interleukin-23
TWI426918B (zh) * 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
SG178804A1 (en) 2007-02-23 2012-03-29 Schering Corp Engineered anti-il-23p19 antibodies
EP2059534B1 (de) 2007-02-23 2012-04-25 Schering Corporation Gentechnisch hergestellte anti-il-23p19-antikörper
JP5337055B2 (ja) 2007-02-28 2013-11-06 メルク・シャープ・アンド・ドーム・コーポレーション 免疫性障害の処置のための組合せ治療
NZ579251A (en) 2007-02-28 2012-06-29 Schering Corp Engineered anti-il-23r antibodies
EP2288621A4 (de) * 2007-07-06 2012-01-04 Valorisation Hsj Soc En Commandite Il23-rezeptor-antagonisten und ihre verwendung
AR068723A1 (es) * 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
JPWO2009054454A1 (ja) 2007-10-24 2011-03-03 国立大学法人 東京医科歯科大学 カテプシン阻害剤を有効成分として含有するＴｏｌｌ様受容体のシグナル伝達の調整剤
KR20150002874A (ko) 2008-05-05 2015-01-07 노비뮨 에스 에이 항-ｉｌ-１７ａ／ｉｌ-１７ｆ 교차-반응성 항체 및 그의 사용 방법
US20110158992A1 (en) * 2008-08-27 2011-06-30 Schering Corporation Engineered Anti-IL-23R Antibodies
US20110183859A1 (en) * 2008-09-25 2011-07-28 The United States Of America, As Represented By The Secretary, Inflammatory genes and microrna-21 as biomarkers for colon cancer prognosis
US20120058108A1 (en) * 2008-10-20 2012-03-08 Kai Krohn Methods and uses involving genetic aberrations of nav3 and aberrant expression of multiple genes
JP2012522749A (ja) * 2009-04-01 2012-09-27 グラクソ グループ リミテッド 抗ｉｌ−２３免疫グロブリン
EP2427203B1 (de) 2009-05-05 2018-10-17 Novimmune S.A. Anti-il-17f-antikörper und deren verwendung
WO2011011797A2 (en) * 2009-07-24 2011-01-27 The Board Of Trustees Of The Leland Stanford Junior University Cytokine compositions and methods of use thereof
US20110086806A1 (en) * 2009-10-09 2011-04-14 Anaphore, Inc. Polypeptides that Bind IL-23R
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
US20110311527A1 (en) 2010-06-16 2011-12-22 Allergan, Inc. IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
EP3456740A1 (de) 2010-11-04 2019-03-20 Boehringer Ingelheim International GmbH Anti-il-23-antikörper
USRE49026E1 (en) 2011-06-14 2022-04-12 Medical Diagnostic Laboratories, Llc Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
US8946150B2 (en) 2011-06-14 2015-02-03 Medical Diagnostic Laboratories, LLC. Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
US11078265B2 (en) 2012-05-03 2021-08-03 Boehringer Ingelheim International Gmbh Anti-IL-23 antibodies
US9803010B2 (en) 2012-06-27 2017-10-31 Merck Sharp & Dohme Corp. Crystalline anti-human IL-23p19 antibodies
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
AR094877A1 (es) 2013-03-08 2015-09-02 Lilly Co Eli Anticuerpos que se unen a il-23
JP2017524359A (ja) 2014-07-24 2017-08-31 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｉｌ−２３ａ関連疾患の処置に有用なバイオマーカー
EA039598B9 (ru) 2014-09-03 2022-03-10 Бёрингер Ингельхайм Интернациональ Гмбх Соединение, нацеленное на ил-23а и фно-альфа, и его применение
AR102417A1 (es) 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
US11279754B2 (en) 2015-03-11 2022-03-22 Rush University Medical Center Compositions and methods for treating cancer
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
SG11201909955XA (en) 2017-05-02 2019-11-28 Merck Sharp & Dohme Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
CN113395979A (zh) 2018-11-20 2021-09-14 詹森生物科技公司 用抗il-23特异性抗体治疗银屑病的安全且有效的方法
EP3972690A4 (de) 2019-05-23 2023-07-05 Janssen Biotech, Inc. Verfahren zur behandlung einer entzündlichen darmerkrankung mit einer kombinationstherapie von antikörpern gegen il-23 und tnf-alpha

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6176962B1 (en) 1990-02-28 2001-01-23 Aclara Biosciences, Inc. Methods for fabricating enclosed microchannel structures
US5783415A (en) 1991-03-29 1998-07-21 Genentech, Inc. Method of producing an IL-8 receptor polypeptide
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
AU6501296A (en) 1995-07-21 1997-02-18 General Hospital Corporation, The Method and apparatus of enhancing the delivery of a pharmaceutical formulation
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6060284A (en) * 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
US5842787A (en) 1997-10-09 1998-12-01 Caliper Technologies Corporation Microfluidic systems incorporating varied channel dimensions
US6326482B1 (en) 1999-04-23 2001-12-04 Genentech, Inc. SH2 domain-containing peptides
WO2000032634A1 (en) 1998-12-01 2000-06-08 Protein Design Labs, Inc. Humanized antibodies to gamma-interferon
ES2300276T5 (es) * 1999-09-09 2017-06-02 Merck Sharp & Dohme Corp. P40 de interleuquina-12 de mamífero e interleuquina B30. Sus combinaciones. Anticuerpos. Usos en composiciones farmacéuticas
ES2307618T3 (es) * 2000-05-10 2008-12-01 Schering Corporation Proteinas subunidades de receptores de cotocinas de mamiferos, reactivos y metodos relacionados.
AU2318202A (en) * 2000-10-06 2002-04-15 Immunex Corp Hematopoietin receptors hpr1 and hpr2
WO2002097048A2 (en) * 2001-05-30 2002-12-05 Centocor, Inc. ANTI-p40 IMMUNOGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES
TWI357336B (en) * 2003-03-10 2012-02-01 Schering Corp Uses of il-23 agonists and antagonists; related re

Also Published As

Publication number Publication date
CN1759123B (zh) 2011-04-13
DE602004022781D1 (de) 2009-10-08
JP2011032275A (ja) 2011-02-17
JP2006520781A (ja) 2006-09-14
EP1601694A2 (de) 2005-12-07
WO2004081190A2 (en) 2004-09-23
CA2518262C (en) 2014-05-06
US20120034219A1 (en) 2012-02-09
WO2004081190A3 (en) 2005-02-03
PT1601694E (pt) 2009-12-03
NZ541898A (en) 2008-07-31
US20080057058A1 (en) 2008-03-06
CA2518262A1 (en) 2004-09-23
JP2007197453A (ja) 2007-08-09
AU2010212372B2 (en) 2012-12-20
SI1601694T1 (sl) 2010-01-29
US7282204B2 (en) 2007-10-16
AU2004219625B9 (en) 2010-12-23
US20040223969A1 (en) 2004-11-11
US20100003251A1 (en) 2010-01-07
JP4605798B2 (ja) 2011-01-05
NZ567860A (en) 2009-11-27
US8034341B2 (en) 2011-10-11
HK1076477A1 (en) 2006-01-20
EP2108658A1 (de) 2009-10-14
EP2108658B1 (de) 2016-06-08
EP1601694B1 (de) 2009-08-26
NO20054630L (no) 2005-10-07
TW200505479A (en) 2005-02-16
ES2330220T3 (es) 2009-12-07
DK1601694T3 (da) 2009-12-14
PL1601694T3 (pl) 2010-02-26
TWI357336B (en) 2012-02-01
AU2004219625A1 (en) 2004-09-23
NO20054630D0 (no) 2005-10-07
TWI439285B (zh) 2014-06-01
CL2004000467A1 (es) 2005-05-06
AU2010212372A1 (en) 2010-09-09
TW201141521A (en) 2011-12-01
CY1109468T1 (el) 2014-08-13
ZA200506879B (en) 2006-05-31
JP2014005286A (ja) 2014-01-16
CN1759123A (zh) 2006-04-12
BRPI0408247A (pt) 2006-03-01
MXPA05009717A (es) 2005-10-18
AU2004219625B2 (en) 2010-08-19

Similar Documents

Publication Publication Date Title
ATE440864T1 (de) Verwendung von il-23-antagonisten; verwandte reagenzien
NO20064193L (no) fremgangsmate for a modulere cytokinaktivitet, beslektede reagenser
BRPI0507794A (pt) métodos de modular a atividade de il-23, reagentes relacionados
NO20063624L (no) FC region varianter
CY1108645T1 (el) Θεραπεια και διαγνωση νεοπλασματων χρησιμοποιωντας θυμικη στρωματικη λεμφοποιητινη
TW200505455A (en) Anti-cancer medicaments
ATE470672T1 (de) Verwendung von cupredoxin-proteine für krebstherapie
DK1454992T3 (da) Anaplastisk lymfomakinaseassay, reagenser og sammensætninger deraf
ATE534902T1 (de) Replikationsproteinn ciz1
ATE427773T1 (de) Verwendung von n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-a1,3,4- xadiazol-2-yluphenyl)pyridin-3- sulphonamid in der tumortherapie
ATE425962T1 (de) Peptid-deformylase-hemmer
ATE312077T1 (de) Peptiddeformylase-hemmer
IS7441A (is) Peptíðdeformýlasatálmar
DE10342518A1 (de) Plasminogen-Aktivatoren mit verringerter Lysin-Bindungskapazität
DE60329931D1 (de) Fprl1-liganden und deren verwendung
DK1708693T3 (da) Farmaceutiske sammensætninger indeholdende platinkomplekser med sekundære xanthater og terapeutiske anvendelser deraf
DE60232650D1 (de) Peptiddeformylaseinhibitoren
CY1116323T1 (el) ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ TNFα-ΣΧΕΤΙΖΟΜΕΝΩΝ ΔΙΑΤΑΡΑΧΩΝ
DE60334078D1 (de) Organische anionentransporter-proteine (oatp/lst) und ihre dna
ATA8972002A (de) Liegeunterlage zur inaktivierung von ektoparasiten
ITRM20020158U1 (it) Apparato duplicatore di sim card.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1601694

Country of ref document: EP